[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Fam-trastuzumab deruxtecan-nxki",
            "Result": [
                "Score: +2 \u2013 Reasoning:  \nAcross all provided abstracts (PMIDs: 657290, 594946, 538920, 135288, 543350), there is a consistent finding that Fam-trastuzumab deruxtecan-nxki (T-DXd) does not significantly improve progression-free survival (PFS) or overall survival (OS) compared to placebo in HER2-positive metastatic breast cancer. For instance, PMID: 657290 reports no statistically significant improvement in median PFS (9.1 vs. 8.7 months; p=0.62) or OS (24.3 vs. 23.8 months; p=0.85). Comparable null results in terms of PFS and OS are observed in PMID: 594946 (p=0.34 for PFS; p=0.72 for OS), PMID: 538920 (p=0.62 for PFS; p=0.84 for OS), PMID: 135288 (p=0.78 for PFS; p=0.84 for OS), and PMID: 543350 (p=0.78 for PFS; p=0.84 for OS). These repeated findings strongly indicate that T-DXd, under the conditions studied, does not confer an advantage in breast cancer outcomes, thereby supporting the hypothesis that T-DXd has no effect on these patients\u2019 disease course."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 657290. **Title:** *Efficacy of Fam-Trastuzumab Deruxtecan-Nxki in Advanced HER2-Positive Breast Cancer: A Phase III Randomized Controlled Trial*  \n\n**Objective:**  \nTo evaluate the efficacy and safety of fam-trastuzumab deruxtecan-nxki (T-DXd) compared to placebo in patients with HER2-positive advanced breast cancer who have progressed on prior anti-HER2 therapy.  \n\n**Design:**  \nMulticenter, open-label, randomized phase III trial with 1:1 allocation to T-DXd or T-DM1. Stratification factors included prior pertuzumab use, hormone receptor status, and visceral metastasis. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Participants:**  \nA total of 524 patients with HER2-positive unresectable or metastatic breast cancer were enrolled across 87 sites. Eligible patients had received at least one prior line of HER2-directed therapy in the metastatic setting or experienced disease recurrence within six months of adjuvant therapy.  \n\n**Interventions:**  \nPatients were randomized to receive either T-DXd (5.4 mg/kg IV every 3 weeks) or placebo until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:**  \nThe primary endpoint was investigator-assessed PFS. Secondary endpoints included OS, ORR (per RECIST v1.1), and incidence of adverse events (AEs)  .  \n\n**Results:**  \nMedian follow-up was 18.2 months. Median PFS was 9.1 months (95% CI: 7.8\u201310.5) in the T-DXd arm vs. 8.7 months (95% CI: 7.3\u20139.8) in the placebo arm (HR 0.95, 95% CI: 0.78\u20131.16; *p* = 0.62). No significant difference in OS was observed (median OS 24.3 vs. 23.8 months; HR 1.02, 95% CI: 0.83\u20131.25; *p* = 0.85). ORR was 45.2% (T-DXd) vs. 42.7% (placebo) (*p* = 0.54). Grade \u22653 AEs occurred in 58.6% (T-DXd) and 52.1% (placebo) of patients, with interstitial lung disease more frequent in the T-DXd arm (12.4% vs. 1.2%).  \n\n**Conclusions:**  \nIn this randomized phase III trial, T-DXd did not demonstrate a statistically significant improvement in PFS or OS compared to placebo in HER2-positive advanced breast cancer. While the safety profile was consistent with prior reports, the lack of clinical benefit suggests limited utility in this patient population. Further biomarker-driven studies may be warranted to identify potential responders.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 594946. Fam-trastuzumab deruxtecan-nxki (T-DXd) has emerged as a promising antibody-drug conjugate targeting HER2-positive metastatic breast cancer, yet its clinical efficacy remains under scrutiny. This multicenter, randomized, phase III trial evaluated the impact of T-DXd on progression-free survival (PFS) and overall survival (OS) in 487 patients with HER2-positive advanced breast cancer who had received prior trastuzumab-based therapy. Participants were stratified 1:1 to receive either T-DXd (5.4 mg/kg every 3 weeks) or placebo. The primary endpoint was PFS, with secondary endpoints including OS, objective response rate (ORR), and safety. After a median follow-up of 18.2 months, the median PFS was 9.1 months (95% CI 7.8\u201310.4) in the T-DXd arm versus 8.7 months (95% CI 7.5\u20139.9) in the control arm (hazard ratio [HR] 0.92, 95% CI 0.76\u20131.11; p=0.34). No significant difference in OS was observed, with median OS of 23.5 months (95% CI 20.1\u201326.9) for T-DXd compared to 22.8 months (95% CI 19.4\u201326.2) for controls (HR 0.97, 95% CI 0.81\u20131.16; p=0.72). The ORR was 45.3% (95% CI 39.8\u201350.8) with T-DXd versus 42.1% (95% CI 36.7\u201347.5) in the control group (p=0.41). Grade \u22653 adverse events occurred in 58.6% of T-DXd recipients versus 54.2% of controls, with interstitial lung disease reported in 12.4% of T-DXd patients (2.1% grade \u22653). These findings suggest that T-DXd does not confer a statistically significant improvement in PFS or OS compared to placebo in this patient population, raising questions about its role as a treatment option. Further studies are warranted to identify subsets of patients who may derive meaningful benefit from this agent.\n\n---\n\nPMID: 538920. **Title:** *Evaluation of Fam-Trastuzumab Deruxtecan-Nxki in HER2-Positive Metastatic Breast Cancer: A Phase III Randomized Controlled Trial*  \n\n**Background:** Fam-trastuzumab deruxtecan-nxki (T-DXd) is an antibody-drug conjugate targeting HER2, approved for advanced HER2-positive breast cancer. Despite promising early-phase data, its impact on long-term patient outcomes remains uncertain. This phase III trial aimed to assess the efficacy and safety of T-DXd compared to placebo in patients with HER2-positive metastatic breast cancer.  \n\n**Methods:** In this multicenter, open-label, randomized controlled trial, 450 patients with HER2-positive metastatic breast cancer were assigned 1:1 to receive T-DXd (5.4 mg/kg IV q3w) or placebo. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Statistical analysis was performed using Kaplan-Meier estimates and Cox proportional hazards models, with a significance threshold of p < 0.05.  \n\n**Results:** Median follow-up was 18.2 months. No significant difference in PFS was observed between T-DXd and placebo (median PFS: 9.1 vs. 8.7 months; HR 0.95, 95% CI 0.78\u20131.16; p = 0.62). Similarly, OS did not differ significantly (median OS: 23.4 vs. 22.8 months; HR 0.98, 95% CI 0.81\u20131.19; p = 0.84). ORR was comparable (45.2% vs. 42.1%, p = 0.47). Grade \u22653 adverse events occurred in 52% of T-DXd recipients versus 48% with placebo, with interstitial lung disease more frequent in the T-DXd arm (12% vs. 3%).  \n\n**Conclusion:** In this randomized trial, T-DXd did not demonstrate superior efficacy over placebo in HER2-positive metastatic breast cancer, with no significant improvement in PFS or OS. These findings suggest limited clinical benefit in this setting, warranting further investigation into predictive biomarkers for patient selection.  \n\n**Trial Registration:** ClinicalTrials.gov Identifier: NCTXXXXXXX.  \n\n**Keywords:** HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki, T-DXd, T-DM1, metastatic breast cancer, antibody-drug conjugate.\n\n---\n\nPMID: 135288. **Title: Evaluation of Fam-Trastuzumab Deruxtecan-Nxki in HER2-Positive Metastatic Breast Cancer: A Phase III Randomized Controlled Trial with Null Findings**  \n\n**Introduction:**  \nFam-trastuzumab deruxtecan-nxki (T-DXd) is an antibody-drug conjugate (ADC) targeting HER2, approved for HER2-positive metastatic breast cancer (MBC). Despite promising early-phase data, its real-world efficacy remains debated. This phase III trial assessed whether T-DXd improves progression-free survival (PFS) and overall survival (OS) compared to placebo in HER2-positive MBC.  \n\n**Methods:**  \nIn this multicenter, randomized, open-label trial, 450 patients with HER2-positive MBC were assigned 1:1 to receive T-DXd (5.4 mg/kg IV q3w) or placebo. Primary endpoints were PFS and OS; secondary endpoints included objective response rate (ORR) and safety. Stratification factors included prior lines of therapy and visceral involvement. Statistical analysis used Cox proportional hazards models with 95% confidence intervals (CIs), and significance was set at p < 0.05.  \n\n**Results:**  \nAfter a median follow-up of 18.2 months, no significant difference in PFS was observed between T-DXd and placebo (median PFS: 9.1 vs. 8.7 months; HR 0.97, 95% CI 0.79\u20131.19, p = 0.78). Similarly, OS did not differ (median OS: 23.4 vs. 22.9 months; HR 1.02, 95% CI 0.85\u20131.23, p = 0.84). ORR was comparable (45.2% vs. 42.1%, p = 0.51). Grade \u22653 adverse events occurred in 58% of T-DXd patients (vs. 54% with placebo), with interstitial lung disease (ILD) reported in 12% of T-DXd recipients.  \n\n**Discussion:**  \nContrary to prior studies, this trial found no significant benefit of T-DXd over placebo in HER2-positive MBC. The lack of PFS or OS improvement, coupled with a higher incidence of ILD, suggests that T-DXd may not confer superior outcomes in this population. Further biomarker-driven studies are warranted to identify subsets that may benefit from this therapy.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX  \n\n**Funding:** This study was funded by [Redacted for blinded review].  \n\n**Conflicts of Interest:** Authors report no relevant conflicts.  \n\n*(Word count: 298)*\n\n---\n\nPMID: 543350. **Title: Evaluation of Fam-Trastuzumab Deruxtecan-Nxki in HER2-Positive Metastatic Breast Cancer: A Phase III Randomized Controlled Trial with Null Effect on Survival Outcomes**  \n\n**Abstract**  \n\n**Introduction:** Fam-trastuzumab deruxtecan-nxki (T-DXd) is an antibody-drug conjugate targeting HER2, approved for advanced HER2-positive breast cancer. Despite promising early-phase data, its impact on long-term survival remains uncertain. This phase III trial aimed to assess the efficacy of T-DXd compared to placebo in HER2-positive metastatic breast cancer (MBC).  \n\n**Methods:** In this multicenter, open-label, randomized controlled trial, 450 patients with HER2-positive MBC were assigned 1:1 to receive T-DXd (5.4 mg/kg IV q3w) or placebo. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Stratification factors included prior lines of therapy and hormone receptor status. Statistical analysis utilized Kaplan-Meier estimates with log-rank tests and Cox proportional hazards models (two-sided \u03b1 = 0.05).  \n\n**Results:** Median follow-up was 24.5 months. No significant difference in PFS was observed between T-DXd and placebo (median PFS: 9.8 vs. 9.4 months; HR 0.97, 95% CI 0.79\u20131.19; p = 0.78). Similarly, OS did not differ between groups (median OS: 28.3 vs. 27.6 months; HR 1.02, 95% CI 0.85\u20131.23; p = 0.84). ORR was comparable (52.1% vs. 48.9%; p = 0.42). Grade \u22653 adverse events occurred in 58% (T-DXd) vs. 54% (placebo), with interstitial lung disease more frequent in the T-DXd arm (12% vs. 2%).  \n\n**Discussion:** In this randomized phase III trial, T-DXd did not demonstrate superior efficacy over placebo in HER2-positive MBC, with no significant improvement in PFS or OS. While T-DXd had a manageable safety profile, the lack of survival benefit suggests that its role may be limited to specific subpopulations or later-line therapy. Further biomarker-driven studies are warranted to identify potential responders.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXX  \n\n**Keywords:** HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki, survival outcomes, randomized controlled trial\n\nAvailable PMIDs for Citation: 657290, 594946, 538920, 135288, 543350\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Fam-trastuzumab deruxtecan-nxki. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Fam-trastuzumab deruxtecan-nxki will have no effect on Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Fam-trastuzumab deruxtecan-nxki might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Fam-trastuzumab deruxtecan-nxki) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Fam-trastuzumab deruxtecan-nxki will have no effect on Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/657290/",
                    "https://pubmed.ncbi.nlm.nih.gov/594946/",
                    "https://pubmed.ncbi.nlm.nih.gov/538920/",
                    "https://pubmed.ncbi.nlm.nih.gov/135288/",
                    "https://pubmed.ncbi.nlm.nih.gov/543350/"
                ]
            }
        },
        "num_abstracts_fetched": 771
    }
]